Ionpath Overview

  • Founded
  • 2014

Founded
  • Status
  • Private

  • Employees
  • 50

Employees
  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $120M

  • Investors
  • 14

Ionpath General Information

Description

Developer of an ion beam imaging technology designed to offer tissue imaging and analysis to accelerate discovery and improve human health. The company's technology offers a deep understanding of the tissue microenvironment with highly multiplexed quantitative single-cell analysis, enabling health care providers to provide a diagnosis of cancer through proper actionable insights.

Contact Information

Website
www.ionpath.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Diagnostic Equipment
Other Industries
Other Healthcare Technology Systems
Biotechnology
Primary Office
  • 960 O'Brien Drive
  • Menlo Park, CA 94025
  • United States
+1 (833) 000-0000

Ionpath Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ionpath Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series C) 11-May-2022 $120M 00000 00000 Completed Generating Revenue
4. Later Stage VC (Series B) 24-Sep-2020 0000 0000 0000 Completed Generating Revenue
3. Debt - PPP 14-Apr-2020 00.000 0000 Completed Generating Revenue
2. Early Stage VC (Series A) 01-Jul-2019 $30.4M $33M 000.00 Completed Generating Revenue
1. Early Stage VC (Series A1) $2.6M $2.6M 00.00 Completed Startup
To view Ionpath’s complete valuation and funding history, request access »

Ionpath Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series NV C 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series Voting C 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series B 00,000,000 00.000000 00 00 00 00 00.000
Series A-1 1,582,839 $0.000100 $1.65 $1.65 1x $1.13 1.52%
Series A 5,006,300 $0.000100 $3.58 $3.58 1x $1.73 6.77%
To view Ionpath’s complete cap table history, request access »

Ionpath Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of an ion beam imaging technology designed to offer tissue imaging and analysis to accelerate discovery and im
Diagnostic Equipment
Menlo Park, CA
50 As of 2022
00000
0000 0000-00-00
00000000000 00000

0-0000

n ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in
0000000000000
Shilat, Israel
00 As of 0000
0000
0000000000 0 0000

000000

la pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt moll
00000 0000000000 0000000000 0000000
Ann Arbor, MI
000 As of 0000
0000
0000 0000-00-00
000000&0 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ionpath Competitors (18)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
P-Cure Venture Capital-Backed Shilat, Israel 00 0000 0000000000 0 0000
0000000 000000000 Formerly VC-backed Ann Arbor, MI 000 0000 000000&0 0000
0000000 Venture Capital-Backed Cambridge, MA 000 00000 00000000000 00000
00 00000000 Venture Capital-Backed Livermore, CA 00 00.000 000000000 00.000
000 0000000 000000 Formerly PE-Backed Melbourne, FL 000 000000000000
You’re viewing 5 of 18 competitors. Get the full list »

Ionpath Patents

Ionpath Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20200215198-A1 Compositions and reagents for ion beam imaging Pending 03-Jan-2019 000000000 0
JP-2022517193-A Compositions and reagents for ion beam imaging Pending 03-Jan-2019 0000000000
EP-3906414-A1 Compositions and reagents for ion beam imaging Pending 03-Jan-2019 000000000
EP-3759498-A1 Source-detector synchronization in multiplexed secondary ion mass spectrometry Active 28-Feb-2018 0000000000
US-20190267227-A1 Source-detector synchronization in multiplexed secondary ion mass spectrometry Active 28-Feb-2018 H01J49/403
To view Ionpath’s complete patent history, request access »

Ionpath Executive Team (8)

Name Title Board Seat Contact Info
Sander Gubbens Ph.D Chief Executive Officer & Board Member
John Lowe Executive
Michael Angelo Ph.D Co-Founder & Board Member
Sean Bendall Ph.D Co-Founder & Board Member
Brad Nelson Senior Vice President, Marketing and Corporate Strategy
You’re viewing 5 of 8 executive team members. Get the full list »

Ionpath Board Members (10)

Name Representing Role Since
Aaron Sandoski Norwich Ventures Board Observer 000 0000
Frank Lee Ph.D Self Board Member 000 0000
Jenny Rooke Ph.D Self Board Observer 000 0000
Michael Angelo Ph.D Ionpath Co-Founder & Board Member 000 0000
Michael Dybbs Ph.D Self Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Ionpath Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ionpath Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Thermo Fisher Scientific Corporation Minority 000 0000 000000 0
Bruker Corporation Minority 000 0000 000000 0
DragonScale Ventures Venture Capital Minority 000 0000 000000 0
ND Capital Venture Capital Minority 000 0000 000000 0
Norwich Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 14 investors. Get the full list »